Skip Nav Destination
Issues
1 May 2012
-
Cover Image
Cover Image
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid (CDDO)-methyl ester (Me) inhibits estrogen receptor-negative mammary carcinogenesis in polyoma middle T (PyMT) mice and inhibits the infiltration of tumor-associated macrophages (TAM) to the mammary glands and tumors of these mice. Beginning at 4 weeks of age, female PyMT mice were fed powdered control diet or CDDO-Me diet (50 mg/kg); the mice were sacrificed at 12 weeks of age. The micropictogram featured on the cover (400 × magnification) shows TAM infiltration detected by F4/80 staining (brown) in PyMT mouse mammary glands; quantification of this infiltration found it to be significantly reduced with the CDDO-Me diet (versus control) in 12-week-old mice. Tumor cells in the mouse mammary glands stained blue. See article by Tran et al. (beginning on page 726) for more information. - PDF Icon PDF LinkTable of Contents
ISSN 1940-6207
EISSN 1940-6215
Issue Sections
Commentary
Research Articles
Allelic Transcripts Dosage Effect in Morphologically Normal Ovarian Cells from Heterozygous Carriers of a BRCA1/2 French Canadian Founder Mutation
Diala Abd-Rabbo; Christine Abaji; Guillaume B. Cardin; Abdelali Filali-Mouhim; Caroline Arous; Lise Portelance; Enrique Escobar; Sophie Cloutier; Patricia N. Tonin; Diane M. Provencher; Anne-Marie Mes-Masson; Christine M. Maugard
Letter to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.